Diabetes mellitus (DM) and Alzheimer’s disease (AD) are two highly prevalent conditions in the elderly population and major
public health burden. In the past decades, a pathophysiological link between DM and AD has emerged and central nervous
system insulin resistance might play a significant role as a common mechanism; however, other factors such as inflammation
and oxidative stress seem to contribute to the shared pathophysiological link. Both preclinical and clinical studies have evaluated
the possible neuroprotective mechanisms of different classes of antidiabetic medications in AD, with some promising results.
Here, we review the evidence on the mechanisms of action of antidiabetic drugs and their potential use in AD.